Approach:
The research relied extensively on secondary sources, including company websites, investor presentations, press releases, product sites, and Clinicaltrials.gov. Specific keywords were used to systematically identify digital therapeutics (DTx) devices within both the approved and active clinical trials. Estimation of the market size and forecast was conducted by analyzing the prevalence of targeted medical conditions, the penetration rates of DTx solutions among relevant patient populations, and the average subscription fee per patient per member per year (PMPY). Market trends for the industry were projected by referencing historical market data and triangulating insights from multiple independent reports. The competitive landscape assessment was performed through a deep review of product portfolios, funding rounds, and strategic partnerships within a universe of leading DTx companies. The research approach allowed for a robust evaluation of current market dynamics, near-term evolution, and the positioning of key players within the rapidly evolving digital health space.
Key findings:
The U.S. digital therapeutics (DTx) market was valued at $1,344 million in 2020 and is projected to expand at a compound annual growth rate (CAGR) of 28%, reaching approximately $4,800 million by 2025. DTx developers are primarily focused on mental health and nervous system (CNS) disorders, followed by oncology, musculoskeletal pain, gastrointestinal, and cardiometabolic conditions. More than 30 companies have multiple DTx products at various stages of clinical development, with actively increasing market uptake. Click Therapeutics emerged as a leader in terms of device portfolio breadth. Notable key players in therapeutics include Pear Therapeutics, Akili Interactive, BigHealth, and Biofourmis.
Business Impact:
The analysis empowered clients to make informed strategic decisions regarding market entry, product development, and commercialization by providing comprehensive market landscape information and key segment data. Information and strategic positioning of the major DTx makers to identify valuable partnership opportunities and establish evidence for digital therapeutics ultimately supporting business growth and competitive differentiation in the digital therapeutic space.